Drug Profile
IO 103
Alternative Names: IO103; PD-L1 peptide vaccineLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator IO Biotech
- Developer Herlev Hospital; IO Biotech
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Basal cell cancer; Chronic lymphocytic leukaemia
- Phase I/II Myeloproliferative disorders
- No development reported Follicular lymphoma; Multiple myeloma
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Follicular lymphoma(Second-line therapy or greater) in Denmark (SC, Injection)
- 28 Feb 2022 Zealand university hospital completes a phase I/II clinical trial in Myeloproliferative disorders (Combination therapy) in Denmark (SC) (EudraCT2019-001434-34)
- 08 Mar 2021 IO Biotech and Herlev Hospital complete a phase II trial in Chronic lymphocytic leukaemia (In adults, In the elderly, Combination therapy, Adjuvant therapy, First-line therapy) in Denmark (SC) (EudraCT2018-004869-14)